A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Key facts

Sponsor

HiberCell, Inc.

Intervention

HC-7366(drug)

Enrollment

80 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (20)

• University of Arizona Cancer Center, Tucson, Arizona, United States
• University of California San Diego Moores Cancer Center, La Jolla, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
• Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
• Yale - New Haven Hospital, New Haven, Connecticut, United States
• HealthPartners Cancer Research Center, Saint Paul, Minnesota, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
• Cleveland Clinic, Cleveland, Ohio, United States
• Providence Cancer Institute, Portland, Oregon, United States
• SCRI Oncology Partners, Nashville, Tennessee, United States
• Texas Oncology, Dallas, Texas, United States
• University of Texas Southwestern Medical Center, Dallas, Texas, United States
• +5 more locations on ClinicalTrials.gov

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →